{
    "eid": "2-s2.0-84940530289",
    "title": "Initiation of antiretroviral therapy in early asymptomatic HIV infection",
    "cover-date": "2015-08-27",
    "subject-areas": [
        {
            "$": "General Medicine",
            "@code": "2700"
        }
    ],
    "keywords": [],
    "authors": [
        "Jens D. Lundgren"
    ],
    "citedby-count": 2235,
    "ref-count": 48,
    "ref-list": [
        "Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome",
        "Curr Opin HIV AIDS",
        null,
        "When to start ART in Africa - An urgent research priority",
        "Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART Study",
        "Early versus standard antiretroviral therapy for HIV-infected adults in Haiti",
        "Prevention of HIV-1 infection with early antiretroviral therapy",
        "Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: Results from the phase 3 HPTN 052 randomised controlled trial",
        "Effect of early versus deferred antiretroviral therapy for HIV on survival",
        "Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies",
        "Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters",
        "When to initiate combined antiretroviral therapy to reduce mortality and aids-defining illness in HIV-infected persons in developed countries",
        "Comparative eff ectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: Observational cohort study",
        "Rating evidence in treatment guidelines: A case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons",
        "When to start antiretroviral therapy: The need for an evidence base during early HIV infection",
        "Early versus deferred antiretroviral therapy for HIV [1]",
        "CD4+ count-guided interruption of antiretroviral treatment",
        "Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: A randomized trial",
        "Combination Antiretroviral Therapy and the Risk of Myocardial Infarction: The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group",
        null,
        "Presented at the Annual Conference on Ret-roviruses and Opportunistic Infections",
        "Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: A combined analysis of 12 mathematical models",
        "90-90-90: An Ambitious Treatment Target to Help End the AIDS Epidemic.",
        "HIV, Universal Health Coverage and the post-2015 Development Agenda",
        "Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study",
        "HIV Med",
        "Guidelines for the Use of Antiretrovi-ral Agents in HIV-1-Infected Adults and Adolescents",
        "Antiretroviral treatment of adult HIV infection: 2014 Recommendations of the International Antiviral Society-USA panel",
        "Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for A Public Health Approach",
        "1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.",
        "Criteria for Event Reporting in START",
        "Reporting and evaluaton of HIV-related clinical endpoints in two multicenter international clinical trials",
        "Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials",
        "A multiple testing procedure for clinical trials",
        "Discrete sequential boundaries for clinical trials",
        "Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial",
        "Attitudes of people in the UK with HIV who are antiretroviral (ART) na\u00efve to starting art at high CD4 counts for potential health benefit or to prevent HIV transmission",
        "Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count",
        "The incidence of AIDS-defining illnesses at a current CD4 count \u2265200 cells/\u03bcL in the post-combination antiretroviral therapy era",
        "Morbidity and mortality according to latest CD4+ cell count among HIV positive individuals in South Africa who enrolled in Project Phidisa",
        "Critical role of CD4 T cells in maintaining lymphoid tissue structure for immune cell homeostasis and reconstitution",
        "Cardiovascular implications from untreated human immunodeficiency virus infection",
        "Changes in inflammatory and coagulation biomarkers: A randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection",
        "Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: A substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial",
        "Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial",
        "Implications of the START Study Data: Questions and Answers"
    ],
    "affiliation": [
        {
            "affiliation-city": "Minneapolis",
            "affilname": "University of Minnesota Twin Cities",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "London",
            "affilname": "University College London",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Bethesda",
            "affilname": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "London",
            "affilname": "HIV i-BASE",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Paris",
            "affilname": "Universit\u00e9 Paris Cit\u00e9",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Entebbe",
            "affilname": "Uganda Virus Research Institute",
            "affiliation-country": "Uganda"
        },
        {
            "affiliation-city": "Copenhagen",
            "affilname": "K\u00f8benhavns Universitet",
            "affiliation-country": "Denmark"
        },
        {
            "affiliation-city": "Badalona",
            "affilname": "Hospital Universitari Germans Trias i Pujol",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Kensington",
            "affilname": "The Kirby Institute",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Koln",
            "affilname": "Uniklinik K\u00f6ln",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Washington, D.C.",
            "affilname": "The George Washington University",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Cape Town",
            "affilname": "University of Cape Town",
            "affiliation-country": "South Africa"
        },
        {
            "affiliation-city": "Rio de Janeiro",
            "affilname": "Projeto Pra\u00e7a Onze",
            "affiliation-country": "Brazil"
        }
    ],
    "funding": [
        "National Institute of Allergy and Infectious Diseases",
        "National Institute of Allergy and Infectious Diseases"
    ]
}